

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: August 18, 2015
(Date of earliest event reported)

CELLECTAR BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

1-36598
(Commission
File Number)

04-3321804
(IRS Employer
Identification Number)

3301 Agriculture Drive
Madison, WI 53716
(Address of principal executive offices)

(608) 441-8120
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 7.01 REGULATION FD DISCLOSURE

On August 18, 2015, the web site BioTuesdays published an interview with James Caruso, the Chief Executive Officer of Celectar Biosciences, Inc. (the “Company”). A copy of the article is furnished as Exhibit 99.1 and is incorporated by reference herein.

On August 21, 2015, the Company issued a press release introducing its Phospholipid ether-Drug Conjugate (“PDC”) platform for expanding the use of its proprietary small-molecule cancer targeting and delivery technology for targeted delivery of chemotherapeutics. A copy of the release is furnished as Exhibit 99.2 and is incorporated by reference herein.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

Number	Title
99.1	BioTuesdays article dated August 18, 2015, entitled “Celectar Biosciences refocusing on therapeutics”
99.2	Press release dated August 21, 2015, entitled “Celectar Biosciences Introduces Phospholipid Ether-Drug Conjugate (PDC) Platform for Targeted Delivery of Chemotherapeutics”

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 21, 2015

CELLECTAR BIOSCIENCES, INC.

By: /s/ Chad J. Kolean

Name: Chad J. Kolean

Title: Vice President and Chief Financial Officer

EXHIBIT INDEX

Number	Title
99.1	BioTuesdays article dated August 18, 2015, entitled “Cellecstar Biosciences refocusing on therapeutics”
99.2	Press release dated August 21, 2015, entitled “Cellecstar Biosciences Introduces Phospholipid Ether-Drug Conjugate (PDC) Platform for Targeted Delivery of Chemotherapeutics”

BT biotuesdays.com<http://biotuesdays.com/2015/08/18/collectar-biosciences-refocusing-on-therapeutics/>

Collectar Biosciences refocusing on therapeutics

By
leonardzehr

After completing a strategic review of its cancer therapeutic and cancer diagnostic assets, Collectar Biosciences (NASDAQ:CLRB) has refocused the company on its phospholipid ether drug conjugate (PDC) platform and cancer-targeting delivery of oncologic payloads.

"We were previously focused on advancing our diagnostic assets, with no plan to take advantage of our cancer therapeutics beyond radiotherapeutics," newly appointed president and CEO, Jim Caruso, says in an interview with BioTuesdays.com.

"We believe our PDC platform has the potential for significant value creation and as a result, we plan to seek collaborators to complete development of our diagnostic imaging agents," he adds.

Mr. Caruso, who joined Collectar in mid-June, explains that PDCs are proprietary small molecule, cancer-targeting delivery vehicles that consist of a cancer selective phospholipid ether, a linker molecule and a drug payload.


"PDCs are a new class of cancer targeting and delivery technology that have the ability to attach diverse oncologic payloads against a broad range of selective cancer and cancer stem cell targets, with the additional advantage of prolonged retention," he contends.

He points out that PDCs are designed to enter cancer cells through the cell cytoplasm and are cancer selective, unlike antibody drug conjugates, which are biologics and target tumor-specific antigens at the cell surface.

"Our PDC cancer targeting has been validated, using cytotoxic radioisotopes for cancer therapy and imaging; fluorophores for imaging-guided surgery; and we now plan to demonstrate similar data with chemotherapeutics such as paclitaxel and gemcitabine, for an improved therapeutic index," he adds.



Proprietary Small-Molecule, Cancer-Targeting Delivery Vehicle



PDCs are proprietary small molecule, cancer-targeting delivery vehicles made up of a cancer selective phospholipid ether, a linker molecule and a drug payload

The company's PDC delivery platform has been peer-reviewed, most recently, in *Neurosurgery* in February 2015 and *Science Translational Medicine* in June 2014. The platform is protected by more than 28 patents issued or pending.

Collectar's lead in-house PDC radiotherapeutic is CLR 131. Its payload is the delivery of iodine 131, a proven cytotoxic radioisotope, which is used primarily for thyroid cancer.

Mr. Caruso says the company has demonstrated *in vivo* tumor uptake, retention and efficacy with CLR 131 in liquid and solid tumors. "We are expanding the indications beyond thyroid cancer and believe we have a very good shot on goal with CLR 131 against multiple myeloma," he contends.


Multiple myeloma is the second most common hematologic cancer, with a prevalence of about 90,000 patients, an incidence of about 27,000 patients, of which some 13,000 are relapse/refractory patients with limited options resulting in a clear unmet medical need.

CLR 131 for relapsed/refractory multiple myeloma has been granted orphan drug designation and has the potential for fast track, breakthrough therapy and accelerated approval.

Mr. Caruso says CLR 131 has the potential for single dose treatment, which is significant in the relapsed/refractory market.

Collectar initiated an open label, Phase 1 dose escalation trial in the second quarter this year. It expects to evaluate a minimum of three patients in the first cohort during the first half of next year and initiate cohort 2 also during the first half of 2016.

The primary objective of the trial is dose-limiting toxicity, with secondary objectives to determine a Phase 2 dose and low dose efficacy read.



Collectar's PDC chemotherapeutic program currently includes two preclinical drug candidates: CLR 1601-PTX, with paclitaxel as the payload, and CLR 1605-GEM, with gemcitabine as the payload.

Mr. Caruso says the company has *in vitro* studies that demonstrate CLR 1601-PTX's stability and cytotoxic activity. Preclinical data for CLR 1601-PTX will be updated in the fourth quarter this year and CLR 1605-GEM in the first quarter next year.

"Our objective with this program is to develop chemotherapy PDCs with improved efficacy and tolerability," he contends.

From a clinical rationale, he suggests there are numerous chemotherapies that are highly effective yet are highly toxic that could

be improved through a PDC targeted delivery.

And from a business rationale, he points to a significant opportunity through clinical development partnerships to create new products, with new patent life and life cycle management.

"There are many companies with therapies that offer great promise but their tolerability has not allowed them to be advanced through the clinic. Our targeting delivery platform may give those molecules a shot on goal," he points out.

In its cancer diagnostic program, Collectar is evaluating value-optimizing pathways for its optical imaging and PET/CT imaging compounds. "In the past, we haven't aggressively shopped these assets but we now plan to reach out to potential partnership candidates who could develop these compounds," Mr. Caruso says.

While Collectar is building its future around CLR 131 as a treatment for multiple myeloma and using its PDC platform to create partnership opportunities, Mr. Caruso says the company reserves the right to advance one or more of its cancer therapeutic products at least through Phase 1 development.

"Our team is focused on a plan to unlock the value of our PDC platform by developing wholly-owned therapeutics, expanding cytotoxic therapeutic windows and advancing our platform through collaborations," he adds.

PDC Product Candidates					
Class	Cancer Therapeutics			Cancer Diagnostics	
Status	Phase 1	Pre-Clinical	Pre-Clinical	Phase 2	Phase 1
PDC	CLR 131	CLR 1601-PTX	CLR 1605-GEM	CLR 124	CLR 1502
Payload	Radiotherapy	Chemotherapy	Chemotherapy	Radioisotope PET/CT Imaging	Fluorophore Optical Imaging
Indication	Multiple Myeloma	Breast and Lung	Pancreatic, Other	Glioma	Breast Cancer Lumpectomy
Status	Enrolling Patients	Internal In Vitro and In Vivo Studies		Evaluating Value-Optimizing Pathways	
Path	In-House	Collaboration Platform			

PDC Product Development Pipeline

Cellectar Biosciences Introduces Phospholipid Ether-Drug Conjugate (PDC) Platform for Targeted Delivery of Chemotherapeutics

Expanding Pipeline of Therapeutic PDC Candidates

Madison, WI (August 21, 2015) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused biotechnology company, recently introduced its Phospholipid ether-Drug Conjugate (PDC) platform for expanding the use of its proprietary small-molecule cancer targeting and delivery technology for targeted delivery of chemotherapeutics.

During the company's second quarter financial results call on August 12th, CEO Jim Caruso unveiled the company's plan for creating capital efficient shareholder value. A key component of this plan leverages the company's core cancer targeting and delivery technology through both early stage internal research and clinical development collaborations.

"PDCs are a new class of small-molecules that exploit our extensively vetted phospholipid ether-based cancer targeting and delivery technology. Our platform possesses the ability to link diverse oncologic payloads for targeted delivery to a broad range of cancer and cancer stem cell targets," said Mr. Caruso.

Cellectar's PDC platform has demonstrated highly selective cancer targeting both preclinically in over 60 *in vivo* cancer models, and subsequently confirmed clinically in over 10 cancer types. The platform's payload diversity has been validated using cytotoxic radioisotopes for cancer therapy; PET imaging isotopes for cancer imaging; fluorophores for image-guided surgery, and now the company plans to expand its payload portfolio to chemotherapeutics such as paclitaxel and gemcitabine.

Cellectar is initiating its PDC chemotherapeutic program with two preclinical drug candidates, CLR 1601-PTX and CLR 1605-GEM, which will utilize paclitaxel and gemcitabine as the respective payloads. Preclinical data for CLR 1601-PTX is expected to be updated in the fourth quarter of 2015 and CLR 1605-GEM in the first quarter of 2016.

"We anticipate generating additional proof of concept data for the PDC chemotherapeutic program. Our PDC platform possesses the potential to enhance the treatment value of new and existing chemotherapeutic agents by providing more targeted drug delivery for improved tolerability and overall therapeutic index," added Mr. Caruso.

Cellectar's lead PDC is CLR 131. Its payload is iodine-131, a proven cytotoxic radioisotope, which is used primarily for thyroid cancer treatment. The company initiated a disease-specific Phase I dose escalation study in patients with relapsed/refractory multiple myeloma this past April, and has been granted orphan drug designation. The company expects to evaluate cohort 1 and initiate cohort 2 during the first half of 2016. The primary objectives of the study are to determine dose-limiting toxicity and identify a Phase II dose, with a secondary objective of observing efficacy signals.

"We remain excited about the clinical potential of our lead PDC, CLR 131. Multiple myeloma is an incurable cancer and the relapsed/refractory setting remains a treatment challenge. We look forward to providing clinicians and patients with a new class of medication, possessing a novel mechanism of action, as an additional treatment option," concluded Mr. Caruso.

Multiple myeloma is the second most common hematologic malignancy and there remains high unmet medical need in the relapsed/refractory setting.

Details of the company's PDC platform and multiple myeloma study can be found by accessing the quarterly conference call recording, or reviewing its updated corporate presentation, both of which can be found at www.cellectar.com located in the "Investor Relations" section.

About Cellectar Biosciences, Inc.

Cellectar Biosciences is developing phospholipid ether-drug conjugates (PDCs) designed to provide cancer targeting delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar's PDC platform is based on the company's proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers and cancer stem cells. Cellectar's PDC pipeline includes product candidates for cancer therapy and diagnostic imaging. The company's lead PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 is currently being evaluated under an orphan drug designated Phase I study in patients with relapsed/refractory multiple myeloma. For additional information please visit www.cellectar.com.

###

This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K/A for the year ended December 31, 2014. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

INVESTOR AND MEDIA CONTACT:

Jules Abraham

JQA Partners

917-885-7378

jabraham@jqapartners.com
